Antares Pharma announced the launch of Xyosted (testosterone enanthate) Injection indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Xyosted, an androgen, was approved by the Food and Drug Administration (FDA) in September 2018. It is intended for once-weekly subcutaneous (SC) injection via a single-dose, disposable QuickShot autoinjector.
Xyosted carries a Boxed Warning describing blood pressure increases that can raise the risk for major cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death. Due to this risk, Xyosted should only be used for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies. Prior to starting Xyosted, the patient’s baseline cardiovascular risk should be considered and blood pressure should be adequately controlled.
Xyosted is a CIII controlled substance. It is available as 50 mg, 75 mg, and 100 mg strength single-dose QuickShot autoinjectors. “To enhance the patient experience during the launch of this novel treatment option, we are putting in place a comprehensive support program that is designed to offer co-pay assistance to most commercially insured patients, as well as benefits investigation and a prior authorization support service for physician’s offices in order to help ensure prescriptions are filled in an efficient manner,” said Robert F. Apple, President and Chief Executive Officer of the Company.
For more information call (844) 996-7833 or visit Xyosted.com.
This article originally appeared on MPR